Exposure –response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations

ConclusionsThese analyses provide important quantitative pharmacologic support for benefit/risk assessment of the 500  mg/day dosage of tepotinib as being appropriate for the treatment of NSCLC harboringMETex14 skipping alterations.Registration NumbersNCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research